| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.sanjivani.co.in | |
| Market Cap | 53.79 Cr. | |
| Enterprise Value(EV) | 56.54 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 6.02 | Trailing Twelve Months Ending 2022-06 |
| Price-Earning Ratio (PE) | 8.94 | Trailing Twelve Months Ending 2022-06 |
| Industry PE | 32.22 | Trailing Twelve Months Ending 2022-06 |
| Book Value / Share | -36.76 | Trailing Twelve Months Ending 2022-06 |
| Price to Book Value | -1.46 | Calculated using Price: 53.80 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 1.00 Cr. | 9,998,300 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Sanjivani Parenteral was established in 1997 by A H Khemka, Ashwin Khemka and Somesh Khemka, under the technical direction of Mahendra Kalwankar. It is a research-based, international pharmaceutical company that provides a wide range of high quality products and services at affordable prices. The core product range of the company's products includes oral solids, small volume parenterals and sterile powder formulations. | ||
| 1 Day |
|
+1.95% |
| 1 Week |
|
+1.57% |
| 1 Month |
|
+16.70% |
| 3 Month |
|
+15.60% |
| 6 Month |
|
-10.59% |
| 1 Year |
|
+80.13% |
| 2 Year |
|
+517.68% |
| 5 Year |
|
+591.68% |
| 10 Year |
|
+115.94% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 7.55 | 4.66 | -7.19 | -58.98 | -596.93 | |||||
| Return on Capital Employed (%) | 13.03 | 12.18 | 5.69 | -7.28 | -33.04 | -227.28 | -265.98 | 266.43 | ||
| Return on Assets (%) | 2.19 | 1.38 | -2.09 | -14.16 | -34.18 | -124.34 | -9.62 | -10.16 | 8.13 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 33 | 35 | 32 | 18 | -9 | -53 | -47 | -49 | -45 | -8 | |
| Non Curr. Liab. | 9 | 8 | 7 | 14 | 9 | 6 | 10 | 9 | 7 | 4 | |
| Curr. Liab. | 71 | 74 | 75 | 62 | 61 | 72 | 56 | 55 | 58 | 22 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 113 | 117 | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 | |
| Non Curr. Assets | 26 | 27 | 16 | 23 | 17 | 16 | 11 | 12 | 10 | 11 | |
| Curr. Assets | 87 | 90 | 98 | 70 | 43 | 9 | 7 | 4 | 9 | 8 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 113 | 117 | 114 | 93 | 60 | 25 | 18 | 16 | 19 | 18 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-06 Rs. Cr. TTM |
| Net Sales | 152 | 159 | 133 | 115 | 33 | 18 | 25 | 16 | 25 | 32 | |
| Other Income | 2 | 3 | 1 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | |
| Total Income | 154 | 161 | 135 | 116 | 36 | 18 | 26 | 17 | 25 | 33 | |
| Total Expenditure | -141 | -149 | -128 | -121 | -56 | -70 | -27 | -17 | -23 | -25 | |
| PBIDT | 13 | 12 | 7 | -5 | -20 | -52 | -1 | 0 | 2 | 7 | |
| Interest | -8 | -8 | -8 | -9 | -5 | 0 | 0 | -1 | 0 | 0 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Exceptional Items | 0 | ||||||||||
| PAT | 2 | 2 | -2 | -15 | -26 | -53 | -2 | -2 | 1 | 6 | |
| Adjusted EPS | 4 | 3 | -4 | -25 | -44 | -90 | -4 | -3 | 2 | 6 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 9 | 7 | 9 | -1 | 0 | 10 | 3 | 2 | 0 | 1 | |
| Cash Fr. Inv. | -8 | -1 | -1 | 9 | -1 | 0 | 0 | 0 | 0 | 0 | |
| Cash Fr. Finan. | -1 | -6 | -8 | -7 | -1 | -10 | -3 | -2 | 0 | 0 | |
| Net Change | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
|
Tue, 09 Aug 2022
Announcement under Regulation 30 (LODR)-Press Release / Media Release Pursuant to Regulation 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 please find enclosed copy of newspaper publication in the following newspapers with respect to Un-Audited Financial Results for the quarter ended June 30 2022 approved at the meeting of Board of Directors held on August 08 2022: 1. Financial Express 2. Prathakal |
|
Mon, 08 Aug 2022
Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 2022 In compliance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 please find enclosed herewith the copy of Un-Audited Financial Results of the Company for the quarter ended 30th June 2022 together with a copy of the Limited Review Report as received from the Statutory Auditors of the Company. The aforesaid Un-Audited Financial Results were approved / taken on record by the Board of Directors at their meeting held on 8th August 2022. The Board meeting commenced at 02.45 pm and concluded at 03.15 pm . |
|
Mon, 01 Aug 2022
Board Meeting Intimation for Quarterly Financial Results SANJIVANI PARANTERAL LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 inter alia to consider and approve 1. The Un-Audited Financial Results of the Company for the quarter ended June 30 2022. 2. Any other matter with the permission of the chair. |
| Tue, 16 Aug 2022 |
High Delivery Percentage
|
Opening at High
|
High Increase 1 Month
|
High Increase 3 Months
|
High Increase 1 Year
|
Equities
M.F.
Sectors